Pyridoxine for prevention of hand–foot syndrome caused by chemotherapy agents: a meta‐analysis
- 15 November 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (4) , 629-635
Abstract
Background Hand–foot syndrome (HFS) is a common systemic skin toxicity syndrome caused by chemotherapy agents. However, there is no uniform clinical treatment for HFS. It is reported that pyridoxine (vitamin B6) can be used to prevent HFS, but the evidence is insufficient. Aim To determine whether pyridoxine can be used to prevent HFS caused by chemotherapy agents. Methods Literature database searches were performed on PubMed, Web of Science, Embase, Cochrane Library and China National Knowledge Infrastructure. The efficacy of pyridoxine was evaluated by the incidence of HFS (any grade) or severe HFS (grade ≥ 2). Results Fourteen studies involving 1570 patients were included in this meta‐analysis. There were no significant differences between the pyridoxine and control groups in the prevention of HFS (OR = 0.84, 95% CI 0.67–1.05, P = 0.09) or in the incidence of grade ≥ 2 HFS (OR = 0.87, 95% CI 0.70–1.09, P = 0.39, respectively). The subgroup analysis of pyridoxine dose also showed no significant difference between the two groups in preventing HFS grade ≥ 2 (OR = 0.79, 95% CI 0.62–0.99, P = 0.30). Conclusions We did not find adequate evidence to support the idea that the use of pyridoxine can prevent HFS and reduce the incidence of HFS grade ≥ 2. However, the preventive use of pyridoxine might have a tendency to reduce the incidence of HFS.Keywords
This publication has 24 references indexed in Scilit:
- Pyridoxine for Prevention of Hand-Foot Syndrome Caused by Chemotherapy: A Systematic ReviewPLOS ONE, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Das Hand‐Fuß‐Syndrom als Nebenwirkung der medikamentösen Tumortherapie – Klassifikation und ManagementJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- A double‐blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin‐related hand‐foot syndrome in gynecologic oncology patientsCancer, 2010
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Pyridoxine as Prophylactic Therapy for Palmar-Plantar Erythrodysesthesia Associated with Administration of Pegylated Liposomal Doxorubicin (Caelyx): A Single-Center ExperienceOncology, 2007
- Oral dexamethasone attenuates Doxil®-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignanciesGynecologic Oncology, 2004
- Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabineJournal of Oncology Pharmacy Practice, 2003
- Pyridoxine Therapy for Palmar-Plantar Erythrodysesthesia Associated With TaxotereJNCI: Journal of the National Cancer Institute, 1993